Effective January 1, 2025, Humira® (adalimumab) or adalimumab biosimilar will no longer be preferred on the Independence Blue Cross (IBX) Value, Select, and Premium Formularies. New prescriptions are now required for patients (our members) on Humira (adalimumab) or adalimumab biosimilars to access the preferred biosimilar indicated below.